Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial

Ronald Dahl, Peter M A Calverley, Antonio Anzueto, Norbert Metzdorf, Andy Fowler, Achim Mueller, Robert Wise, Daniel Dusser, Ronald Dahl, Peter M A Calverley, Antonio Anzueto, Norbert Metzdorf, Andy Fowler, Achim Mueller, Robert Wise, Daniel Dusser

Abstract

Objectives: This post hoc analysis of TIOtropium Safety and Performance In Respimat (TIOSPIR) evaluated safety and exacerbation efficacy in patients with stable (≥ 2 months) use of tiotropium HandiHaler 18 µg (HH18) prior to study entry, to evaluate whether there was a difference in risk for patients who switched from HH18 to tiotropium Respimat 2.5 µg (R2.5) or 5 g (R5).

Setting: TIOSPIR (n=17,135) was an international, Phase IIIb/IV, randomised, double-blind, parallel-group, event-driven trial.

Participants: Patients from TIOSPIR with chronic obstructive pulmonary disease (COPD) and postbronchodilator ratio of forced expiratory volume in 1 s to forced vital capacity ≤ 0.70, receiving HH18 before study entry, were analysed (n=2784).

Interventions: Patients were randomised to once-daily tiotropium R2.5 (n=914), R5 (n=918) or HH18 (n=952) for 2-3 years.

Primary outcomes: time to death (safety) and time to first COPD exacerbation (efficacy).

Secondary outcomes: number of exacerbations and time to first major adverse cardiovascular event (MACE).

Results: Baseline characteristics were similar in all groups. Respimat had a similar mortality risk versus HH18 (vital status follow-up, HR; 95% CI R2.5: 0.87; 0.64 to 1.17; R5: 0.79; 0.58 to 1.07) with no significant differences in the risk and rates of exacerbations and severe exacerbations across treatment groups. Risk of MACE and fatal MACE was similar for Respimat versus HH18 (HR; 95% CI MACE R2.5: 0.73; 0.47 to 1.15; R5: 0.69; 0.44 to 1.08; fatal MACE R2.5: 0.57; 0.27 to 1.19; R5: 0.67; 0.33 to 1.34). Overall risk of a fatal event (on treatment) was lower for R5 versus HH18 (HR; 95% CI R2.5: 0.78; 0.55 to 1.09; R5: 0.62; 0.43 to 0.89).

Conclusions: This analysis indicates that it is safe to switch patients from tiotropium HandiHaler to tiotropium Respimat, and that the efficacy is maintained over the switch.

Trial registration number: NCT01126437; Post-results.

Keywords: COPD; Efficacy; HandiHaler®; Respimat®; Switching; Tiotropium.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Kaplan–Meier plot of time to death by treatment (vital status analysis).

References

    1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2014.
    1. Boehringer Ingelheim. Summary of Product Characteristics: Spiriva 18 microgram inhalation powder, hard capsule 2013.
    1. Boehringer Ingelheim. Summary of Product Characteristics: Spiriva Respimat 2.5 micrograms solution for inhalation 2014.
    1. Hohlfeld JM, Sharma A, van Noord JA et al. . Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol 2014;54:405–14. 10.1002/jcph.215
    1. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;7:CD009285 10.1002/14651858.CD009285.pub3
    1. Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs 2012;72:273–300. 10.2165/11208620-000000000-00000
    1. Keating GM. Tiotropium Respimat® Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs 2014;74:1801–16. 10.1007/s40265-014-0307-4
    1. Tashkin DP, Celli B, Senn S et al. . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543–54. 10.1056/NEJMoa0805800
    1. Boehringer Ingelheim. Tiotropium (Spiriva) Respimat: evaluation of fatal events 2010.
    1. Dong YH, Lin HH, Shau WY et al. . Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013;68:48–56. 10.1136/thoraxjnl-2012-201926
    1. Loke YK, Singh S. Risks associated with tiotropium in chronic obstructive pulmonary disease: overview of the evidence to date. Ther Adv Drug Saf 2012;3:123–31. 10.1177/2042098612438388
    1. Mathioudakis AG, Chatzimavridou-Grigoriadou V, Evangelopoulou E et al. . Comparative mortality risk of tiotropium administered via HandiHaler or Respimat in COPD patients: are they equivalent? Pulm Pharmacol Ther 2014;28:91–7. 10.1016/j.pupt.2014.04.009
    1. Singh S, Loke YK, Enright PL et al. . Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011;342:d3215 10.1136/bmj.d3215
    1. Verhamme KM, Afonso A, Romio S et al. . Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. Eur Respir J 2013;42:606–15. 10.1183/09031936.00005813
    1. Celli B, Decramer M, Kesten S et al. . Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:948–55. 10.1164/rccm.200906-0876OC
    1. Kesten S, Celli B, Decramer M et al. . Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis 2009;4:397–409. 10.2147/COPD.S4802
    1. Beasley R. Tiotropium Respimat increases the risk of mortality: pro. Eur Respir J 2013;42:584–9. 10.1183/09031936.00042113
    1. Wise RA, Anzueto A, Calverley P et al. . The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res 2013;14:40 10.1186/1465-9921-14-40
    1. Wise RA, Anzueto A, Cotton D et al. . Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369:1491–501. 10.1056/NEJMoa1303342
    1. Trotta F, Da Cas CR, Rajevic M et al. . Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study. BMJ Open 2015;5:e006619 10.1136/bmjopen-2014-006619
    1. Dahl R, Schmidt H, Koenen-Bergmann M et al. . Mixed treatment analysis comparing Tiotropium HandiHaler® and Respimat®. Poster (P-925) presented at ERS 2014, Munich, Germany.
    1. Hohlfeld JM, Furtwaengler A, Koenen-Bergmann M et al. . Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG Data From Four Randomized Clinical Trials. Int J Clin Pract 2015;69:72–80.
    1. Halpin D, Dahl R, Hallmann C et al. . Tiotropium HandiHaler® And Respimat®. COPD: a safety analysis on pooled data [Abstract]. Presented at ATS International Conference; 2014, San Diego, California, USA.
    1. Barnes NC, Jones PW, Davis KJ. Safety of tiotropium through the HandiHaler: why did meta-analyses and database studies appear to give a false alarm? Thorax 2014;69:598–9. 10.1136/thoraxjnl-2014-205155
    1. Tashkin DP, Metzdorf N, Hallman C et al. . Safety of tiotropium in renally impaired patients. Eur Respir J 2014;44:(Suppl 58), Abstract 923.
    1. Miravitlles M, Price D, Rabe KF et al. . Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015;10:549–64. 10.2147/COPD.S71913

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner